<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="15651">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00124020</url>
  </required_header>
  <id_info>
    <org_study_id>0019</org_study_id>
    <nct_id>NCT00124020</nct_id>
  </id_info>
  <brief_title>Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus</brief_title>
  <acronym>ATTAIN2</acronym>
  <official_title>A Phase 3, Randomized, Double-Blind, Parallel-Group, Multinational Trial of Intravenous Telavancin Versus Vancomycin for Treatment of Hospital-Acquired Pneumonia With a Focus on Patients With Infections Due to Methicillin-Resistant Staphylococcus Aureus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma Antibiotics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma Antibiotics, Inc.</source>
  <oversight_info>
    <authority>Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica</authority>
    <authority>Argentina: Human Research Bioethics Committee</authority>
    <authority>Argentina: Ministry of Health</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Australia: Human Research Ethics Committee</authority>
    <authority>Australia: National Health and Medical Research Council</authority>
    <authority>Brazil: Ethics Committee</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Brazil: National Committee of Ethics in Research</authority>
    <authority>Brazil: National Health Surveillance Agency</authority>
    <authority>Bulgaria: Bulgarian Drug Agency</authority>
    <authority>Bulgaria: Ministry of Health</authority>
    <authority>Canada: Canadian Institutes of Health Research</authority>
    <authority>Canada: Ethics Review Committee</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Canada: Ministry of Health &amp; Long Term Care, Ontario</authority>
    <authority>Chile: Comisión Nacional de Investigación Científica y Tecnológica</authority>
    <authority>Chile: Instituto de Salud Pública de Chile</authority>
    <authority>China: Ethics Committee</authority>
    <authority>China: Ministry of Health</authority>
    <authority>China: National Natural Science Foundation</authority>
    <authority>China: Food and Drug Administration</authority>
    <authority>Croatia: Agency for Medicinal Product and Medical Devices</authority>
    <authority>Croatia: Ethics Committee</authority>
    <authority>Croatia: Ministry of Health and Social Care</authority>
    <authority>Croatia: Ministry of Science, Education and Sports</authority>
    <authority>Czech Republic: Ethics Committee</authority>
    <authority>Czech Republic: State Institute for Drug Control</authority>
    <authority>Estonia: The State Agency of Medicine</authority>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <authority>France: Direction Générale de la Santé</authority>
    <authority>France: French Data Protection Authority</authority>
    <authority>France: Haute Autorité de Santé Transparency Commission</authority>
    <authority>France: Institutional Ethical Committee</authority>
    <authority>France: Ministry of Health</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>Georgia: Ministry of Health</authority>
    <authority>Greece: Ethics Committee</authority>
    <authority>Greece: Ministry of Health and Welfare</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Israel: Ethics Commission</authority>
    <authority>Israel: Israeli Health Ministry Pharmaceutical Administration</authority>
    <authority>Israel: Ministry of Health</authority>
    <authority>Israel: The Israel National Institute for Health Policy Research and Health Services Research</authority>
    <authority>Korea: Food and Drug Administration</authority>
    <authority>Korea: Ministry for Health and Welfare</authority>
    <authority>Lebanon: Institutional Review Board</authority>
    <authority>Lebanon: Ministry of Public Health</authority>
    <authority>Lithuania: Bioethics Committee</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Mexico: Ethics Committee</authority>
    <authority>Mexico: Federal Commission for Protection Against Health Risks</authority>
    <authority>Mexico: Federal Commission for Sanitary Risks Protection</authority>
    <authority>Mexico: Ministry of Health</authority>
    <authority>Mexico: National Council of Science and Technology</authority>
    <authority>Mexico: National Institute of Public Health, Health Secretariat</authority>
    <authority>Philippines: Bureau of Food and Drugs</authority>
    <authority>Philippines: Department of Health</authority>
    <authority>Poland: Ethics Committee</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Poland: Ministry of Science and Higher Education</authority>
    <authority>Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</authority>
    <authority>Romania: Ethics Committee</authority>
    <authority>Romania: Ministry of Public Health</authority>
    <authority>Romania: National Authority for Scientific Research</authority>
    <authority>Romania: National Medicines Agency</authority>
    <authority>Romania: State Institute for Drug Control</authority>
    <authority>Russia: Ethics Committee</authority>
    <authority>Russia: FSI Scientific Center of Expertise of Medical Application</authority>
    <authority>Russia: Ministry of Health of the Russian Federation</authority>
    <authority>Russia: Pharmacological Committee, Ministry of Health</authority>
    <authority>Serbia and Montenegro: Agency for Drugs and Medicinal Devices</authority>
    <authority>Serbia: Ethics Committee</authority>
    <authority>Slovakia: State Institute for Drug Control</authority>
    <authority>South Africa: Department of Health</authority>
    <authority>South Africa: Human Research Ethics Committee</authority>
    <authority>South Africa: Medicines Control Council</authority>
    <authority>South Africa: National Health Research Ethics Council</authority>
    <authority>Spain: Comité Ético de Investigación Clínica</authority>
    <authority>Spain: Ethics Committee</authority>
    <authority>Spain: Ministry of Health</authority>
    <authority>Spain: Ministry of Health and Consumption</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>Thailand: Ethical Committee</authority>
    <authority>Thailand: Food and Drug Administration</authority>
    <authority>Thailand: Khon Kaen University Ethics Committee for Human Research</authority>
    <authority>Thailand: Ministry of Public Health</authority>
    <authority>Ukraine: Ministry of Health</authority>
    <authority>Ukraine: State Pharmacological Center - Ministry of Health</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study 0019 (NCT00124020) compares the safety and effectiveness of an investigational drug,
      telavancin, with vancomycin for the treatment of hospital-acquired pneumonia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical Response</measure>
    <time_frame>7-14 days following end of antibiotic treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure - at least one of the following:
Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy
Termination of study med due to &quot;lack of efficacy&quot;
Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">771</enrollment>
  <condition>Bacterial Pneumonia</condition>
  <arm_group>
    <arm_group_label>Telavancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telavancin</intervention_name>
    <description>Telavancin 10 mg/kg/day IV for up to 21 days</description>
    <arm_group_label>Telavancin</arm_group_label>
    <other_name>TD6424</other_name>
    <other_name>VIBATIV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days</description>
    <arm_group_label>Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical signs and symptoms consistent with pneumonia acquired after at least 48
             hours of continuous stay in an inpatient acute or chronic care facility or acquired
             within 7 days after being discharged from a hospitalization of greater than or equal
             to 3 days duration.

        Exclusion Criteria:

          -  Received more than 24 hours of potentially effective systemic (IV, IM or PO)
             antibiotic therapy for Gram-positive pneumonia immediately prior to randomization.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>G. Ralph Corey, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center, Infectious Disease Unit</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>May 2010</verification_date>
  <lastchanged_date>May 14, 2010</lastchanged_date>
  <firstreceived_date>July 22, 2005</firstreceived_date>
  <firstreceived_results_date>November 3, 2009</firstreceived_results_date>
  <responsible_party>
    <name_title>Steven L. Barriere, Pharm.D., Vice President, Clinical and Medical Affairs</name_title>
    <organization>Theravance, Inc.</organization>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Bacterial</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Telavancin</mesh_term>
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment Period: 23 January 2005 to 02 May 2007</recruitment_details>
      <pre_assignment_details>14 patients (9 telavancin and 5 vancomycin) enrolled in the study but never started study treatment</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs</description>
        </group>
        <group group_id="P2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV every 12 hrs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="377"/>
                <participants group_id="P2" count="380"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="289"/>
                <participants group_id="P2" count="289"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="67"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transfer to another hospital</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs</description>
        </group>
        <group group_id="B2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV every 12 hrs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="377"/>
                <measurement group_id="B2" value="380"/>
                <measurement group_id="B3" value="757"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="182"/>
                <measurement group_id="B2" value="184"/>
                <measurement group_id="B3" value="366"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="195"/>
                <measurement group_id="B2" value="196"/>
                <measurement group_id="B3" value="391"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="61" spread="17.8"/>
                <measurement group_id="B2" value="62" spread="18.0"/>
                <measurement group_id="B3" value="62" spread="17.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="125"/>
                <measurement group_id="B2" value="124"/>
                <measurement group_id="B3" value="249"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="252"/>
                <measurement group_id="B2" value="256"/>
                <measurement group_id="B3" value="508"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Argentina</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="19"/>
                <measurement group_id="B3" value="39"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Australia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
                <measurement group_id="B2" value="14"/>
                <measurement group_id="B3" value="23"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Brazil</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="16"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Bulgaria</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Canada</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Chile</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>China</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="27"/>
                <measurement group_id="B2" value="37"/>
                <measurement group_id="B3" value="64"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Croatia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Czech Republic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Estonia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>France</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Georgia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="17"/>
                <measurement group_id="B2" value="13"/>
                <measurement group_id="B3" value="30"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Greece</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Israel</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="38"/>
                <measurement group_id="B2" value="38"/>
                <measurement group_id="B3" value="76"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Korea, Republic of</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="53"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Lebanon</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Lithuania</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Mexico</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Philippines</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Poland</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="4"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Romania</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="4"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="7"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Russian Federation</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="21"/>
                <measurement group_id="B2" value="29"/>
                <measurement group_id="B3" value="50"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Serbia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="17"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Slovakia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>South Africa</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Spain</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="2"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Thailand</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="22"/>
                <measurement group_id="B2" value="11"/>
                <measurement group_id="B3" value="33"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Ukraine</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="12"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
                <measurement group_id="B2" value="46"/>
                <measurement group_id="B3" value="106"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Diabetes Status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Diabetic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="69"/>
                <measurement group_id="B2" value="65"/>
                <measurement group_id="B3" value="134"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-Diabetic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="308"/>
                <measurement group_id="B2" value="315"/>
                <measurement group_id="B3" value="623"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>History of Pneumonia</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Prior history of pneumonia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="37"/>
                <measurement group_id="B2" value="45"/>
                <measurement group_id="B3" value="82"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>No prior history of pneumonia</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="340"/>
                <measurement group_id="B2" value="335"/>
                <measurement group_id="B3" value="675"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ventilator Status</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Ventilated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="175"/>
                <measurement group_id="B2" value="175"/>
                <measurement group_id="B3" value="350"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Non-ventilated</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="202"/>
                <measurement group_id="B2" value="205"/>
                <measurement group_id="B3" value="407"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response</title>
        <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure - at least one of the following:
Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy
Termination of study med due to “lack of efficacy”
Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
        <time_frame>7-14 days following end of antibiotic treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Telavancin</title>
            <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs</description>
          </group>
          <group group_id="O2">
            <title>Vancomycin</title>
            <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV every 12 hrs.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="377"/>
                  <measurement group_id="O2" value="380"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Clinical Response</title>
            <description>Clinical Response: Categorical (Cured, Failed or Indeterminate)
Failure - at least one of the following:
Persistence or progression of signs and symptoms of pneumonia that still require antibiotic therapy
Termination of study med due to “lack of efficacy”
Death on or after Day 3 attributable to primary infection
Cure: Signs and symptoms of pneumonia improved to the point that no further antibiotics for pneumonia were required, and baseline radiographic findings improved or did not progress.
Indeterminate: Inability to determine outcome</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Cured</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="227"/>
                  <measurement group_id="O2" value="228"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Failure</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="53"/>
                  <measurement group_id="O2" value="52"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Indeterminate</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="39"/>
                  <measurement group_id="O2" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Missing</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="58"/>
                  <measurement group_id="O2" value="62"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority>Yes</non_inferiority>
            <non_inferiority_desc>Non-inferiority margin of 20% was specified based on historical regulatory precedent.</non_inferiority_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-6.8</ci_lower_limit>
            <ci_upper_limit>7.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Two patients were randomized to vancomycin, yet were treated with telavancin. For analyses of efficacy, results were analyzed according to the treatment group assigned by randomization. For safety analyses, results were analyzed according to treatment received; 379 patients received telavancin and 378 patients received vancomycin.</desc>
      <group_list>
        <group group_id="E1">
          <title>Telavancin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP) (primarily due to MRSA) were randomized to receive telavancin 10 mg/kg IV every 24 hrs</description>
        </group>
        <group group_id="E2">
          <title>Vancomycin</title>
          <description>Patients with Gram-positive hospital acquired pneumonia (HAP)(primarily due to MRSA) were randomized to receive vancomycin 1 Gm IV every 12 hrs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiogenic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ischaemic cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wandering pacemaker</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Mesenteric Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hepatocellular damage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bacterial Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Candida Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Lung Infection pseudomonal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Meningitis Candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Peritonitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sinusitis fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Superinfection Lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Systemic candida</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anastomotic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Post-operative ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tracheostomy malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Traumatic brain injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Wound Evisceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood sodium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bile Duct cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Multiple Myeloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oesophageal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Small Cell Lung Cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cerebellar Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cerebral ischemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Intracranial Pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Neurological Symptom</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental Status Changes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Airways Disease Exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumothorax Spontaneous Tension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulmonary Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Throat secretion increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="295" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="296" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thrombocythaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anasarca</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Oral Candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Post-Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Post-Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal Impairment</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Renal Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Distress Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Dependence on Respirator</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Decubitis Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="378"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="379"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="378"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Steve Barriere, Pharm.D., Vice President, Clinical and Medical Affairs</name_or_title>
      <organization>Theravance, Inc</organization>
      <phone>650-808-6132</phone>
      <email>sbarriere@theravance.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
